|
The drug discovery effort for neurodegenerative
diseases has been one of the major challenges and
focuses of the pharmaceutical industry, which has
been evidenced by fast and dynamic research and
development in this field. Though several clinical
trials for Alzheimer's failed in the last couple
of years, there has been great progress in the
development of novel therapeutic approaches and
targets to treat Alzheimer's as well as
Parkinson's, Huntington's, multiple sclerosis,
stroke and various other neurodegenerative
diseases. Some of these novel approaches include
biomarkers, stem cell therapy, protein misfolding
and aggregation, immunotherapy, vaccines for
Alzheimer's, BACE inhibitors, and much more. There
have also been significant developments in our
understanding of the genetics, the molecular
mechanisms and signaling pathways contributing to
neuronal dysfunction, neurotoxicity and pathology.
At GTC's 6th Neurodegenerative Conditions
Research and Development, leading scientists and
experts will discuss the latest breakthroughs, new
drug targets, new models, the development of new
biomarkers, imaging modalities, and several other
novel developments and therapeutics to combat
neurodegenerative conditions.
|
Home
From basic clinical research to case studies. 
Check out our upcoming Webinar: 
